Private practice with Dr Seth BilazarianView all posts »
Anticoagulation in AF: Fork in the road or four-way stop?Jul 5, 2012 11:00 EDT
The FDA's recent decisions on novel anticoagulants in atrial fibrillation have stirred debate and generated some consternation. For the clinical practitioner, how do the new agents really stack up to warfarin? Dr Bilazarian proposes KISS-CRABI:
- K - Keep
- I - It
- S - Simple
- S - Silly
- C - Prescription coverage?
- R - Normal renal function?
- A - Early adopter?
- B - GI bleeding?
- I - Instability on warfarin?
To download Dr Bilazarian's presentation, click here.
To download Dr Bilazarian's comparative Excel sheet, click here.
- There is something strange about apixaban
- Apixaban (Eliquis) was supposed to beat dabigatran (Pradaxa) and rivaroxaban (Xarelto). . . . What gives?
- #48: Focus on novel anticoagulants in clinical practice with Dr Elaine Hylek
- FDA refuses ACS indication for rivaroxaban—for now
- Apixaban delay prompts "not-us!" chorus